CN112351785A - 利用人脐带组织来源的间充质基质细胞治疗自闭症谱系障碍的方法 - Google Patents

利用人脐带组织来源的间充质基质细胞治疗自闭症谱系障碍的方法 Download PDF

Info

Publication number
CN112351785A
CN112351785A CN201980033345.8A CN201980033345A CN112351785A CN 112351785 A CN112351785 A CN 112351785A CN 201980033345 A CN201980033345 A CN 201980033345A CN 112351785 A CN112351785 A CN 112351785A
Authority
CN
China
Prior art keywords
hct
months
msc
cells
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980033345.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·库茨贝格
G·道森
J·孙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68101425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112351785(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duke University filed Critical Duke University
Publication of CN112351785A publication Critical patent/CN112351785A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Educational Technology (AREA)
  • Hospice & Palliative Care (AREA)
CN201980033345.8A 2018-04-04 2019-04-04 利用人脐带组织来源的间充质基质细胞治疗自闭症谱系障碍的方法 Pending CN112351785A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652722P 2018-04-04 2018-04-04
US62/652,722 2018-04-04
PCT/US2019/025716 WO2019195506A1 (en) 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (1)

Publication Number Publication Date
CN112351785A true CN112351785A (zh) 2021-02-09

Family

ID=68101425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980033345.8A Pending CN112351785A (zh) 2018-04-04 2019-04-04 利用人脐带组织来源的间充质基质细胞治疗自闭症谱系障碍的方法

Country Status (12)

Country Link
US (1) US12491210B2 (https=)
EP (1) EP3773486B1 (https=)
JP (1) JP2021520380A (https=)
KR (1) KR20210031853A (https=)
CN (1) CN112351785A (https=)
AU (1) AU2019247210A1 (https=)
BR (1) BR112020020295A2 (https=)
CA (1) CA3096033A1 (https=)
ES (1) ES2968823T3 (https=)
IL (1) IL277733B2 (https=)
SG (1) SG11202009805PA (https=)
WO (1) WO2019195506A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057969A (zh) * 2021-03-09 2021-07-02 吴志新 一种间充质干细胞对儿童自闭症临床应用实验方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9347956B2 (en) 2010-12-16 2016-05-24 Autism Biotech Limited Biomarker and uses thereof in diagnosis, treatment of autism
AU2017235446A1 (en) 2016-03-16 2018-11-08 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
US20170296588A1 (en) * 2016-04-19 2017-10-19 AngioStem, Inc. Mesenchymal stem cells derived from placental sources
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
US10987381B2 (en) 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BENJAMIN GESUNDGEIT等: "Therapeutic properties of mesenchymal stem cells for autism spectrum disorders", 《MED HYPOTHESES》 *
DARIO SINISCALCO等: "Autism Spectrum Disorders:Is Mesenchymal Stem Cell Personalized Therapy the Future?", 《J BIOMED BIOTECHNOL》 *
DARIO SINISCALCO等: "Mesenchymal stem cells in treating autism:Novel insights", 《WORLD J STEM CELLS》 *
JESSICA MS等: "Infusion of Human Umbilical Cord Tissue Mesenchymal Stromal Cells in Children With Autism Spectrum Disorder", 《STEM CELLS TRANSL MED》 *
LV YT等: "Transplantation of Human Cord Blood Mononuclear Cells and Umbilical Cord-Derived Mesenchymal Stem Cells in Autism", 《JOURNAL OF TRANSLATIONAL MEDICINE》 *
刘敏等: "干细胞治疗自闭症:安全性和有效性观察", 《中国组织工程研究与临床康复》 *
刘敏等: "脐血单个核细胞和脐带间充质干细胞治疗儿童孤独症的安全性与有效性", 《中国组织工程研究与临床康复》 *
宋秀军等: "干细胞治疗小儿自闭症研究进展(文献综述)", 《放射免疫学杂志》 *
郇英等: "异常行为量表评估干细胞治疗儿童孤独症的临床疗效及效度评价", 《中国医药生物技术》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057969A (zh) * 2021-03-09 2021-07-02 吴志新 一种间充质干细胞对儿童自闭症临床应用实验方法

Also Published As

Publication number Publication date
CA3096033A1 (en) 2019-10-10
EP3773486A1 (en) 2021-02-17
BR112020020295A2 (pt) 2021-01-12
IL277733B1 (en) 2024-06-01
AU2019247210A1 (en) 2020-11-05
EP3773486B1 (en) 2023-12-06
IL277733A (en) 2020-11-30
US20210128631A1 (en) 2021-05-06
SG11202009805PA (en) 2020-11-27
IL277733B2 (en) 2024-10-01
US12491210B2 (en) 2025-12-09
KR20210031853A (ko) 2021-03-23
WO2019195506A1 (en) 2019-10-10
JP2021520380A (ja) 2021-08-19
ES2968823T3 (es) 2024-05-14
EP3773486A4 (en) 2021-12-15
EP3773486C0 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
Tanaka et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan
Prasad et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes
Dawson et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial
Selden et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis
Schlosser-Brandenburg et al. Influence of nutrition and maternal bonding on postnatal lung development in the newborn pig
US12491210B2 (en) Methods of assessing and treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
US11813294B2 (en) Methods for the treatment of autism spectrum disorders
AU2019247383B2 (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
HK40045701A (en) Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Mazalon et al. The significance of medical history and its impact on the early diagnosis of inborn errors of immunity
Gesundheit et al. Mesenchymal stromal cell treatment alleviates autism spectrum disorder symptoms: a case report
Bui Investigation of de-novo copy number variants in patients with Autism Spectrum Disorder in Vietnam
Klancir et al. 492 Can benign afebrile convulsions associated with mild gastroenteritis be prevented by vaccination?
HK40044465A (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Guareschi et al. GUCY2D-Associated Retinopathy: A Comparative Study Between Humans and German Spitz Dogs
Kinsella Haematopoietic Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis Type IIIA
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood
Babinski Allogeneic Mesenchymal Stromal Cell Infusions Are Safe and Effective in Children with Autism Spectrum
Church et al. Abnormal filipin staining and phenotypic overlap between acid sphingomyelinase deficiency and Niemann-Pick C disease
Gauthier Mesenchymal Stem Cell Transplantation: A Novel Approach to Treating Progressive Neurological Diseases
Biglari et al. The Clinical Features and Diagnosis of Canavan's Disease: A Case Series of Iranian Patients
Ebomoyi Neonatal screening for sickle cell disease, caveats about potential cure with innovative medical technology and the relevant evidence-based health education

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045701

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210209

WD01 Invention patent application deemed withdrawn after publication